Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262) (In Press)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
323985.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 1MB |
Abstract
Background: Patients recently hospitalized for heart failure (HF) are at a higher risk of adverse clinical outcomes, but they may experience a greater absolute and relative benefit from effective therapies than individuals who are considered more “stable.” Objectives: The authors examined the effects of dapagliflozin according to the timing of prior HF hospitalization in a patient-level pooled analysis of DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure). Methods: A total of 11,007 patients were randomized in DAPA-HF and DELIVER. The primary outcome was the composite of worsening HF or cardiovascular death. Results: In total, 12.4% were hospitalized for HF within 3 months of randomization, 14.2% between 3 and 12 months, and 16.8% more than 1 year before randomization, whereas 56.5% had not been hospitalized. The risk of the primary endpoint was inversely associated with time from prior HF hospitalization, and patients with a recent HF hospitalization had the highest risk. Compared with placebo, dapagliflozin reduced the risk of the primary outcome across HF hospitalization category (0-3 months, HR: 0.66 [95% CI: 0.55-0.81]; 3-12 months, HR: 0.73 [95% CI: 0.59-0.90]; >1 year, HR: 0.91 [95% CI: 0.74-1.12]; and no prior hospitalization, HR: 0.83 [95% CI: 0.73-0.94]; Pinteraction = 0.09). The number of patients needed to treat with dapagliflozin to prevent 1 event over the median follow-up of 22 months was 13, 20, 23, and 28, respectively. The beneficial effect was consistent across the range of LVEF regardless of HF hospitalization category. Conclusions: The relative benefits of dapagliflozin were consistent across the range of LVEF regardless of the timing of the most recent HF hospitalization with a greater absolute benefit in patients with recent hospitalization.
| Item Type: | Articles |
|---|---|
| Additional Information: | The DAPA-HF and DELIVER trials were funded by AstraZeneca. Profs McMurray and Jhund are supported by a British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217 and the Vera Melrose Heart Failure Research Fund. |
| Status: | In Press |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Butt, Mr Jawad and Docherty, Dr Kieran and Jhund, Professor Pardeep and McMurray, Professor John and Kober, Professor Lars |
| Authors: | Butt, J., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S.P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Kosiborod, M. N., Desai, A. S., Køber, L., Ponikowski, P., Sabatine, M. S., Solomon, S. D., and McMurray, J. J.V. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | JACC: Heart Failure |
| Publisher: | Elsevier |
| ISSN: | 2213-1779 |
| ISSN (Online): | 2213-1787 |
| Published Online: | 03 April 2024 |
| Copyright Holders: | Copyright: © 2024 The Authors |
| First Published: | First published in JACC: Heart Failure 2024 |
| Publisher Policy: | Reproduced under a Creative Commons licence |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information